Axa S.A. Atara Biotherapeutics, Inc. Transaction History

Axa S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $127,513 - $190,366	-10,635 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$12.89 - $16.58 $497,554 - $639,987	-38,600 Reduced 78.4%	10,635 $165,000
Q1 2021 May 14, 2021	SELL	$14.0 - $20.72 $2.07 Million - $3.06 Million	-147,820 Reduced 75.01%	49,235 $707,000
Q4 2020 Feb 12, 2021	SELL	$12.67 - $26.23 $40,544 - $83,936	-3,200 Reduced 1.6%	197,055 $3.87 Million
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $792,156 - $1.57 Million	105,200 Added 110.67%	200,255 $2.92 Million
Q1 2020 May 15, 2020	SELL	$5.69 - $17.78 $243,788 - $761,784	-42,845 Reduced 31.07%	95,055 $809,000
Q4 2019 Feb 18, 2020	BUY	$10.89 - $16.79 $1.29 Million - $1.98 Million	118,165 Added 598.76%	137,900 $2.27 Million
Q3 2019 Nov 14, 2019	BUY	$12.03 - $19.94 $237,412 - $393,515	19,735 New	19,735 $279,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.13B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.